IPO Listed — 01 Sep 2026
Listing Price: ₹988
Symbiotec Pharmalab IPO GMP History | Listing Price ₹988 & Kostak Rate
Symbiotec Pharmalab IPO has been listed on September 1, 2026 at a listing price of ₹988, against the issue price of ₹988 — a gain of ₹0 (+0%). The GMP peaked at ₹410 on 22 August 2026 and reached a low of ₹185 on 1 September 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Symbiotec Pharmalab IPO raised ₹1757 Cr. through its IPO at a price band of ₹938 to ₹988 per share, with a lot size of 15 shares. The IPO was open for subscription from 24 Aug 2026 to 27 Aug 2026.
GMP Trend Chart
Day-wise GMP Trend
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 01 Sep 2026 | ₹ 185 | 18.72% | ₹ 0 | ₹ 0 | |
| 31 Aug 2026 | ₹ 185 | 18.72% | ₹ 0 | ₹ 0 | |
| 30 Aug 2026 | ₹ 240 | 24.29% | ₹ 0 | ₹ 0 | |
| 29 Aug 2026 | ₹ 240 | 24.29% | ₹ 0 | ₹ 0 | |
| 28 Aug 2026 | ₹ 265 | 26.82% | ₹ 0 | ₹ 0 | |
| 27 Aug 2026 | ₹ 270 | 27.33% | ₹ 0 | ₹ 0 | |
| 26 Aug 2026 | ₹ 295 | 29.86% | ₹ 0 | ₹ 0 | |
| 25 Aug 2026 | ₹ 352 | 35.63% | ₹ 0 | ₹ 0 | |
| 24 Aug 2026 | ₹ 335 | 33.91% | ₹ 0 | ₹ 0 | |
| 23 Aug 2026 | ₹ 409 | 41.40% | ₹ 0 | ₹ 0 | |
| 22 Aug 2026 | ₹ 410 | 41.50% | ₹ 0 | ₹ 0 | |
| 21 Aug 2026 | ₹ 345 | 34.92% | ₹ 0 | ₹ 0 | |
| 20 Aug 2026 | ₹ 300 | 30.36% | ₹ 0 | ₹ 0 | |
| 19 Aug 2026 | ₹ 220 | 22.27% | ₹ 0 | ₹ 0 |
Symbiotec Pharmalab IPO Dates
| Event | Date |
|---|---|
| Open Date | 24 Aug, 2026 |
| Close Date | 27 Aug, 2026 |
| Allotment Date | 28 Aug, 2026 |
| Refund Date | 31 Aug, 2026 |
| Credit to Demat | 31 Aug, 2026 |
| Listing Date | 01 Sep, 2026 |
Symbiotec Pharmalab IPO Actual Listing Price
| Basis | Value |
|---|---|
| Issue Price | ₹988 |
| GMP-Based Estimate (Pre-Listing) | ₹1173 (+18.7%) |
| Actual Listing Price | ₹988 (+0%) |
| Listing Gain / Loss | +₹0 per share |
| Listing Date | 01 Sep, 2026 |
Is Symbiotec Pharmalab IPO GMP Reliable?
Grey market premium for Symbiotec Pharmalab IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- Cross-check before acting: Review the Symbiotec Pharmalab IPO full review for a fundamentals-based assessment before making any grey market trades.
Symbiotec Pharmalab IPO IPO Kostak Rate Explained
The Kostak rate for Symbiotec Pharmalab IPO was not active during the subscription period, as no grey market premium was established. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not active for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Symbiotec Pharmalab IPO
The company started in 1995 as a small lab scale maker of steroidal hormone APIs and has grown into a large backward integrated manufacturer with more than 30 years of experience in the field. It is a global leader in corticosteroid and steroidal hormone APIs.
Its plants are approved by the United States Food and Drug Administration, by European Union Good Manufacturing Practices and by the Ministry of Food and Drug Safety of Korea, among other regulators. As on 30 June 2025 it ran two industrial scale API plants with a chemical synthesis capacity of 584.67 metric tonnes and a fermentation capacity of 300 kilolitres. It sells both in India and abroad, in regulated as well as emerging markets.
Strengths & Risks
Strengths
- ✓ The company is a global leader in corticosteroid and steroidal hormone APIs, which is a specialised area with few makers worldwide.
- ✓ Its plants carry approvals from the US FDA, EU-GMP and the Korean drug regulator, which are hard to get and act as an entry barrier.
- ✓ Sales have grown every year, from Rs 723.33 crore in FY2024 to Rs 755.98 crore in FY2025 and Rs 872.26 crore in FY2026.
- ✓ EBITDA has improved steadily, from Rs 177.04 crore in FY2024 to Rs 206.11 crore in FY2025 and Rs 231.97 crore in FY2026.
- ✓ Borrowing was reduced sharply in the last year, from Rs 540.92 crore to Rs 387.91 crore, while net worth rose from Rs 821.15 crore to Rs 1,158.64 crore.
- ✓ The company is backward integrated and runs at industrial scale, with chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres.
- ✓ It has more than 30 years of experience in this line, having started as a lab scale steroid API maker in 1995.
- ✓ It sells into both regulated markets such as the USA and Europe and into emerging markets, so demand is not tied to one region.
Risks
- ⚠ This is by far the most expensive issue in the current batch on earnings. At the upper band of Rs 988 the P/E is about 56.81 times on an EPS of Rs 17.39.
- ⚠ Return ratios are low for that valuation. RoCE was 11.80% and RoNW was 11.79%.
- ⚠ Profit has been almost flat for three years, at Rs 100.06 crore in FY2024, Rs 96.79 crore in FY2025 and Rs 109.90 crore in FY2026, even though assets grew from Rs 1,294.79 crore to Rs 1,780.79 crore over the same period.
- ⚠ Very little of the issue money reaches the company. The stated objects account for only Rs 112.50 crore of borrowing repayment plus general corporate purposes, against a total issue of Rs 1,757 crore, which indicates that most of the issue is an offer for sale by existing shareholders.
- ⚠ The pre issue and post issue promoter holding is not stated in the available data, so the extent of promoter dilution is not clear.
- ⚠ API making is a regulated business. A negative inspection by the US FDA or the EU authorities at either plant can stop supply to those markets.
- ⚠ The company is concentrated in steroid and corticosteroid APIs. A price fall or new capacity in that narrow segment would hit it directly.
- ⚠ Borrowing is still sizeable at Rs 387.91 crore, and it had risen to Rs 540.92 crore in FY2025 before coming down, so the debt level has moved around a lot.
Frequently Asked Questions about Symbiotec Pharmalab IPO
What is the GMP of Symbiotec Pharmalab IPO?
The current Grey Market Premium (GMP) of Symbiotec Pharmalab IPO is ₹ 185.
What is the Kostak Price of Symbiotec Pharmalab IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Symbiotec Pharmalab IPO is currently not available.
What is the Subject to Sauda Price of Symbiotec Pharmalab IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is currently not available.
What was the actual listing price of Symbiotec Pharmalab IPO?
Symbiotec Pharmalab IPO listed on September 1, 2026 at ₹988, against the issue price of ₹988 — a gain of +0%.
How did the GMP of Symbiotec Pharmalab IPO trend before listing?
The GMP of Symbiotec Pharmalab IPO was stable in its final days before listing. The GMP peaked at ₹410 on 22 August 2026. View the day-wise table above for the complete GMP history.
Explore Symbiotec Pharmalab IPO Further
For a complete picture before making your investment decision, explore these resources:
